We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

188 hedge funds and large institutions have $2.57B invested in Audentes Therapeutics, Inc in 2019 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

533% more funds holding in top 10

Funds holding in top 10: 319 (+16)

105% more capital invested

Capital invested by funds: $1.25B → $2.57B (+$1.32B)

87% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 46

26% more funds holding

Funds holding: 149188 (+39)

21% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 39

85% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $82.4M

Holders
188
Holders Change
+39
Holders Change %
+26.17%
% of All Funds
3.7%
Holding in Top 10
19
Holding in Top 10 Change
+16
Holding in Top 10 Change %
+533.33%
% of All Funds
0.37%
New
86
Increased
47
Reduced
39
Closed
46
Calls
$12.5M
Puts
$82.4M
Net Calls
-$69.9M
Net Calls Change
-$68.8M

BOLD Hedge Fund Activity: Q4 2019 in Review

188 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2019, worth a combined $2.57B — up 105% from $1.25B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new BOLD positions and 46 closed out — a net gain of 40 holders — while 47 added to existing stakes and 39 trimmed.

The largest buyer was Magnetar Financial, opening a new position worth an estimated $59.8M. The largest seller was Redmile Group, cutting an estimated $87.2M.

  • 188 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2019, up from 149 in Q3 2019.
  • Funds reported $2.57B of Audentes Therapeutics, Inc stock for Q4 2019, up 105% quarter-over-quarter.
  • 86 funds opened new Audentes Therapeutics, Inc positions in Q4 2019 and 46 closed out, a net change of +40 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q4 2019 was Magnetar Financial, an estimated $59.8M added.
  • The largest Audentes Therapeutics, Inc seller in Q4 2019 was Redmile Group, an estimated $87.2M sold.

Based on aggregated 13F filings for Q4 2019.